The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Vitality Biopharma Publishes Scientific Data on Discovery of Cannabinoid Glycosides
Feb. 01, 2017 08:00AM PST
Biotech InvestingVitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the publication of a scientific manuscript that details internal research efforts including the discovery and production …
Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the publication of a scientific manuscript that details internal research efforts including the discovery and production of cannabinoid glycosides.
The scientific manuscript is titled, “Cannabinoid glycosides: In vitro production of a new class of cannabinoids with improved physicochemical properties,” which details the scientific pathway undertaken by the Company’s research and development team towards the discovery of a multifunctional plant enzyme from Stevia rebaudiana, as well as an ability to produce a diverse class of cannabinoid compounds known as cannabinoid glycosides, or cannabosides. The manuscript has been published through bioRxiv’s Biochemistry section on New Results, which focuses on advances in life sciences research. The full manuscript can be found here: https://biorxiv.org/content/early/2017/01/30/104349.
Small molecule glycosylation is increasingly recognized within the pharmaceutical and biotechnology industries as a reliable means to alter the solubility and stability of drug compounds. Glycosylation may enable prodrug development strategies that extend patent life, improve the bioavailability of existing medications, and reduce side effects through targeted drug delivery.
Traditionally, most pharmaceutical companies employ chemical synthesis methods, but chemical glycosylation is often ineffective due to the need for complex multistep synthetic routes that deliver inadequate yields. In 2013, Vitality Biopharma initiated a research program to overcome this key hurdle, and developed efficient means of glycosylation through enzymatic biosynthesis. In late 2015 and 2016, Vitality scientists applied this technology towards cannabinoids, including cannabidiol (CBD) and tetrahydrocannabinol (THC), creating a new class of cannabinoid glycosides called “cannabosides.”
Vitality has already filed for intellectual property covering the subject matter described in this work, including composition of matter claims for more than 20 cannabinoid glycoside compounds. Cannabosides are now being developed as pharmaceuticals for the treatment of inflammatory bowel disease and narcotic bowel syndrome, a severe form of opiate-induced abdominal pain.
About Vitality Biopharma (OTCQB: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
The scientific manuscript is titled, “Cannabinoid glycosides: In vitro production of a new class of cannabinoids with improved physicochemical properties,” which details the scientific pathway undertaken by the Company’s research and development team towards the discovery of a multifunctional plant enzyme from Stevia rebaudiana, as well as an ability to produce a diverse class of cannabinoid compounds known as cannabinoid glycosides, or cannabosides. The manuscript has been published through bioRxiv’s Biochemistry section on New Results, which focuses on advances in life sciences research. The full manuscript can be found here: https://biorxiv.org/content/early/2017/01/30/104349.
Small molecule glycosylation is increasingly recognized within the pharmaceutical and biotechnology industries as a reliable means to alter the solubility and stability of drug compounds. Glycosylation may enable prodrug development strategies that extend patent life, improve the bioavailability of existing medications, and reduce side effects through targeted drug delivery.
Traditionally, most pharmaceutical companies employ chemical synthesis methods, but chemical glycosylation is often ineffective due to the need for complex multistep synthetic routes that deliver inadequate yields. In 2013, Vitality Biopharma initiated a research program to overcome this key hurdle, and developed efficient means of glycosylation through enzymatic biosynthesis. In late 2015 and 2016, Vitality scientists applied this technology towards cannabinoids, including cannabidiol (CBD) and tetrahydrocannabinol (THC), creating a new class of cannabinoid glycosides called “cannabosides.”
Vitality has already filed for intellectual property covering the subject matter described in this work, including composition of matter claims for more than 20 cannabinoid glycoside compounds. Cannabosides are now being developed as pharmaceuticals for the treatment of inflammatory bowel disease and narcotic bowel syndrome, a severe form of opiate-induced abdominal pain.
About Vitality Biopharma (OTCQB: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact
Vitality Biopharma
Investor Relations
info@vitality.bio
1-530-231-7800
www.vitality.bio
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.